Central European Journal of Immunology最新文献_第3页

Systemic lupus erythematosus in a patient with 22q11.2 deletion syndrome: A case report and review of the literature. 22q11.2缺失综合征患者的系统性红斑狼疮1例报告及文献复习。

IF 1.5 4区医学

Central European Journal of Immunology Pub Date : 2024-01-01 Epub Date: 2024-11-08 DOI: 10.5114/ceji.2024.143229

Chen Sun, Pingyang Han, Juzhen Yan

{"title":"Systemic lupus erythematosus in a patient with 22q11.2 deletion syndrome: A case report and review of the literature.","authors":"Chen Sun, Pingyang Han, Juzhen Yan","doi":"10.5114/ceji.2024.143229","DOIUrl":"10.5114/ceji.2024.143229","url":null,"abstract":"22q11.2 deletion syndrome (MIM: 192430/188400, ORPHA: 567) is the most common chromosomal microdeletion disorder, caused by a hemizygous microdeletion of 2.5 million base pairs on chromosome 22. There is a known association between 22q11.2 deletion syndrome (22q11.2DS), immunodeficiency and autoimmune diseases. However, the co-occurrence of 22q11.2DS and systemic lupus erythematosus (SLE) has been rarely reported. Here, we describe a case of a female teenager with distal type I 22q11.2DS who presented with alopecia, oral ulcers, fever and thrombocytopenia. Laboratory tests showed positive antinuclear antibodies (ANA) and double-stranded DNA (ds-DNA) antibodies, indicative of SLE. Treatment with prednisone, hydroxychloroquine and azathioprine resulted in improvement. We reviewed the literature on the immunological mechanisms involved in 22q11.2DS. Thymic dysplasia, T-cell lymphopenia, and B-cell abnormalities collectively contribute to the immunodeficiency and autoimmune manifestations observed in individuals with 22q11.2DS. Genetic factors such as 22q11.2DS should be considered in the diagnosis of childhood rheumatic diseases. Our case adds to the limited literature on this co-occurrence.","PeriodicalId":9694,"journal":{"name":"Central European Journal of Immunology","volume":"49 3","pages":"315-319"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142885062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Peripheral blood lymphocyte immunophenotyping (TBNK) - a comparison of BD FACSCanto II and BD FACSLyric flow cytometry analysers. 外周血淋巴细胞免疫分型（TBNK）--BD FACSCanto II 和 BD FACSLyric 流式细胞仪的比较。

IF 1.3 4区医学

Central European Journal of Immunology Pub Date : 2024-01-01 Epub Date: 2024-03-05 DOI: 10.5114/ceji.2024.135939

Aleksandra Wiśniewska, Julia Stańczyk, Urszula Demkow, Anna Stelmaszczyk-Emmel

{"title":"Peripheral blood lymphocyte immunophenotyping (TBNK) - a comparison of BD FACSCanto II and BD FACSLyric flow cytometry analysers.","authors":"Aleksandra Wiśniewska, Julia Stańczyk, Urszula Demkow, Anna Stelmaszczyk-Emmel","doi":"10.5114/ceji.2024.135939","DOIUrl":"10.5114/ceji.2024.135939","url":null,"abstract":"Introduction: Flow cytometry immunophenotyping is a common laboratory technique for evaluating lymphocyte subpopulations. Its result remains an important diagnostic tool in various medical fields. Cytometric tests are performed in many laboratories, making the comparability between different devices using the same method an important aspect. We aimed to compare the results of lymphocyte immunophenotyping (lymphocytes B, T, Th and Tc, NK cells) between two different flow cytometers.Material and methods: The study included 93 patients of the Children's Teaching Hospital of the Medical University of Warsaw and 9 Multi-Check control results. The method of lymphocyte subpopulation assessment was based on fluorescent flow cytometry immunophenotyping, using a BD Multitest 6-color TBNK kit (Becton Dickinson). We compared BD FACSCanto II and BD FACSLyric analysers (Becton Dickinson). For data analysis, we used Spearman's rank correlation, Bland-Altman plot and Passing-Bablok regression.Results: Spearman's rank correlation showed a strong interrelation for all analysed parameters (0.808-0.985). In the Passing-Bablok regression analysis, all examined parameters showed linear dependence with the slope values close to 1 (0.940-1.134). Bland-Altman coefficient values were within the range of 2.94-8.62% with half of them being above 5% (T, Tc, Th, B, NKT absolute values and B percentage values).Conclusions: The results from both cytometers can be considered equivalent, but it should be noted that one of the statistical methods showed some deviations, presumably primarily due to the evaluators' different gating techniques. The training of specialists performing these tests requires more attention.","PeriodicalId":9694,"journal":{"name":"Central European Journal of Immunology","volume":"49 1","pages":"45-51"},"PeriodicalIF":1.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11130988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141173688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CSF3R as a potential prognostic biomarker and immunotherapy target in glioma. CSF3R 作为胶质瘤潜在的预后生物标记物和免疫疗法靶点。

IF 1.5 4区医学

Central European Journal of Immunology Pub Date : 2024-01-01 Epub Date: 2024-06-21 DOI: 10.5114/ceji.2024.140651

Minglei Huang, Longze Zhang, Yan Wu, Xue Zhou, Yanyang Wang, Jidong Zhang, Ye Liu, Zhixu He, Xianyao Wang

{"title":"CSF3R as a potential prognostic biomarker and immunotherapy target in glioma.","authors":"Minglei Huang, Longze Zhang, Yan Wu, Xue Zhou, Yanyang Wang, Jidong Zhang, Ye Liu, Zhixu He, Xianyao Wang","doi":"10.5114/ceji.2024.140651","DOIUrl":"https://doi.org/10.5114/ceji.2024.140651","url":null,"abstract":"Introduction: Gliomas are the most common malignant brain tumors, with complicated etiology and poor prognosis. However, there is still a lack of specific biomarkers for the diagnosis, treatment and prognosis assessment for glioma patients. Hence, the purpose of this study was to screen biomarkers for prognostic assessment and therapeutic interventions in gliomas.Material and methods: We utilized The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases to investigate the role of colony-stimulating factor 3 receptor (CSF3R) in glioma. Data analysis was conducted using R, GEPIA 2, TISCH and DepMap.Results: CSF3R was up-regulated in glioma and associated with the clinical pathological features of the patients. Kaplan-Meier survival analysis indicated a significant association between the expression of CSF3R and prognosis in patients. Univariate and multivariate Cox analyses revealed that patients with high expression of CSF3R have a worse prognosis, and the expression of CSF3R was an independent prognostic factor in gliomas. The nomogram constructed based on the expression of CSF3R demonstrated lower 1-, 3-, and 5-year overall survival (OS) in patients with high CSF3R expression. The biological functional analysis of CSF3R demonstrated its association with various immune regulatory signals. Furthermore, CSF3R was linked to the expression of immune checkpoints and resistance to immunotherapy. Notably, CSF3R was predominantly detected in monocytes/macrophages.Conclusions: Our study suggested that CSF3R might potentially function as an independent prognostic factor for glioma and hold promise as a biomarker and target for immunotherapy in glioma.","PeriodicalId":9694,"journal":{"name":"Central European Journal of Immunology","volume":"49 2","pages":"155-168"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457564/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effect of periodontal health and disease on interleukin 1β and nesfatin-1 levels in gingival crevicular fluid: A cross-sectional study. 牙周健康和疾病对牙龈龈沟液中白细胞介素 1β 和内司蛋白-1 水平的影响：一项横断面研究。

IF 1.5 4区医学

Central European Journal of Immunology Pub Date : 2024-01-01 Epub Date: 2024-07-10 DOI: 10.5114/ceji.2024.140637

Meral Uzunkaya, Eda Çetin Özdemir, Hasan Gündoğar, Ergül Belge Kurutaş

{"title":"The effect of periodontal health and disease on interleukin 1β and nesfatin-1 levels in gingival crevicular fluid: A cross-sectional study.","authors":"Meral Uzunkaya, Eda Çetin Özdemir, Hasan Gündoğar, Ergül Belge Kurutaş","doi":"10.5114/ceji.2024.140637","DOIUrl":"https://doi.org/10.5114/ceji.2024.140637","url":null,"abstract":"Introduction: Periodontitis, a chronic inflammatory disease associated with dental biofilm, poses a significant threat to oral health. This study explores the roles of interleukin 1β (IL-1β) and nesfatin-1 in periodontal diseases, aiming to contribute to the molecular understanding of their pathogenesis.Material and methods: A diverse cohort of 62 participants was recruited, spanning ages 20 to 60, and categorized into healthy, gingivitis, and periodontitis groups. Clinical measurements, including plaque index, gingival index, probing pocket depth, and bleeding on probing, were conducted. Gingival crevicular fluid (GCF) samples were collected for IL-1β and nesfatin-1 analysis using enzyme-linked immunosorbent assay (ELISA). Statistical analysis employed Kruskal-Wallis and Spearman correlation tests.Results: Significant differences in oral hygiene habits were observed among groups, particularly in the 40-60 age range. Clinical indices showed variations, with the highest IL-1β levels in the periodontitis group and the lowest nesfatin-1 levels. Correlation analysis revealed positive associations between IL-1β, nesfatin-1, and oral indices.Conclusions: While providing valuable insights, we acknowledge this study's limitations, including a cross-sectional design and a specific age range. Future research should employ longitudinal designs and larger cohorts, and explore broader inflammatory markers, genetic influences, and confounding variables for a more comprehensive understanding of periodontal diseases. The findings underscore the complex interplay between inflammatory markers and periodontal health.","PeriodicalId":9694,"journal":{"name":"Central European Journal of Immunology","volume":"49 2","pages":"187-193"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

LncRNA DLEU1 contributes to the progression of septic myocardial dysfunction by targeting miR-381-3p. LncRNA DLEU1通过靶向miR-381-3p参与脓毒性心肌功能障碍的进展。

IF 1.5 4区医学

Central European Journal of Immunology Pub Date : 2024-01-01 Epub Date: 2024-11-12 DOI: 10.5114/ceji.2024.144199

Tian Tian, Na Zhang, Guoxin Hu, Rong Lu, Jian Liu

{"title":"LncRNA DLEU1 contributes to the progression of septic myocardial dysfunction by targeting miR-381-3p.","authors":"Tian Tian, Na Zhang, Guoxin Hu, Rong Lu, Jian Liu","doi":"10.5114/ceji.2024.144199","DOIUrl":"10.5114/ceji.2024.144199","url":null,"abstract":"Introduction: Cardiac dysfunction is a common complication of sepsis. This study aimed to elucidate the regulatory effect of DLEU1 on sepsis-induced myocardial injury.Material and methods: HL-1 cardiomyocytes were treated with lipopolysaccharide (LPS) to mimic sepsis-induced myocardial injury in vitro, and the mouse septic model was established through cecum ligation and perforation (CLP). Cell viability was evaluated using Cell Counting Kit-8 (CCK-8), while apoptosis was assessed via Annexin-V staining. Pro-inflammatory factors including tumor necrosis factor α (TNF-α), interleukin (IL)-1 β, IL-6, and oxidative stress indicators were detected by ELISA kits. Cardiac function in mice was determined using cardiac ultrasound, and myocardial indices were detected by ELISA.Results: DLEU1 levels were up-regulated gradually in HL-1 cardiomyocytes after LPS treatment in a dose-dependent manner, along with the overactivation of inflammatory responses and oxidative stress. DLEU1 downregulation alleviated LPS-induced cell apoptosis, inflammatory response and oxidative stress. In vivo, DLEU1 knockdown improved the cardiac function of septic mice, and alleviated inflammation and oxidative stress. MiR-381-3p, acting as a competing endogenous RNA (ceRNA) of DLEU1, reversed the effects of DLEU1 in both septic cell and mouse models.Conclusions: The results indicate that the DLEU1/miR-381-3p axis is an intrinsic regulator of myocardial injury in sepsis.","PeriodicalId":9694,"journal":{"name":"Central European Journal of Immunology","volume":"49 3","pages":"227-237"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142885015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New T-lymphocyte subpopulations and their characteristics: Challenges to the classical division of lymphocyte function. 新的t淋巴细胞亚群及其特征：对传统淋巴细胞功能分裂的挑战。

IF 1.5 4区医学

Central European Journal of Immunology Pub Date : 2024-01-01 Epub Date: 2024-11-09 DOI: 10.5114/ceji.2024.144071

Filip Lewandowski, Paulina Niedźwiedzka-Rystwej

{"title":"New T-lymphocyte subpopulations and their characteristics: Challenges to the classical division of lymphocyte function.","authors":"Filip Lewandowski, Paulina Niedźwiedzka-Rystwej","doi":"10.5114/ceji.2024.144071","DOIUrl":"10.5114/ceji.2024.144071","url":null,"abstract":"Recent advances in immunology have challenged the conventional division of T-lymphocyte function by uncovering novel subpopulations with diverse roles and characteristics. This article reviews these discoveries and their implications for understanding immune regulation and disease pathogenesis. Innovative techniques have enabled the identification of previously unrecognized T-lymphocyte subsets, disrupting the classical classification system. Helper lymphocytes, including Tfh1, Tfh2, Tfh17, GC-Tfh, and circulating Tfh cells, exhibit distinct functions in immune responses and disease states. Additionally, newly identified cytotoxic T-cell subsets, such as CD8+CD39+ and CD8+CD28+ cells, demonstrate unique effector properties with potential therapeutic applications in cancer immunothe- rapy. Furthermore, the discovery of CD20+ T cells challenges traditional views, offering new avenues for immunotherapy in cancer, autoimmune disorders, and infectious diseases. These findings expand our understanding of T-lymphocyte biology and suggest targets for more effective therapeutic interventions. Further research is essential to fully elucidate the clinical relevance and therapeutic potential of these T-lymphocyte subpopulations, paving the way for personalized and targeted immune-based treatments.","PeriodicalId":9694,"journal":{"name":"Central European Journal of Immunology","volume":"49 3","pages":"308-314"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664807/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142885034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unveiling the interplay between influenza vaccination and SARS-CoV-2 immune responses. 揭示流感疫苗接种与 SARS-CoV-2 免疫反应之间的相互作用。

IF 1.5 4区医学

Central European Journal of Immunology Pub Date : 2024-01-01 Epub Date: 2024-05-09 DOI: 10.5114/ceji.2024.139512

Jacek Tabarkiewicz, Urszula Radzikowska, Andrzej Eljaszewicz

引用次数: 0

Differential diagnosis of eosinophilic oesophagitis variants and biomarker identification: current progress.

IF 1.5 4区医学

Central European Journal of Immunology Pub Date : 2024-01-01 Epub Date: 2024-11-13 DOI: 10.5114/ceji.2024.143996

Bartosz Hanczaruk, Aleksandra Roszko, Kamil Kamiński, Marlena Tynecka

{"title":"Differential diagnosis of eosinophilic oesophagitis variants and biomarker identification: current progress.","authors":"Bartosz Hanczaruk, Aleksandra Roszko, Kamil Kamiński, Marlena Tynecka","doi":"10.5114/ceji.2024.143996","DOIUrl":"10.5114/ceji.2024.143996","url":null,"abstract":"Eosinophilic oesophagitis (EoE) is a disease characterized by dysregulated type 2 (T2) immune responses with enormous eosinophilic infiltration restricted to the oesophagus. Currently, the gold standard for EoE diagnosis involves identification of oesophageal dysfunction symptoms followed by the detection of at least 15 infiltrating eosinophils per high-power field in the oesophagus. Unfortunately, achieving 90% sensitivity in EoE histology-based diagnosis requires 5-6 biopsy samples to be collected from both the distal and proximal oesophagus, hindering precise diagnosis in routine clinical practice. Therefore, the development of novel diagnostic approaches differentiating EoE from other EoE-like diseases as well as identifying active and non-active forms of EoE is required. In line with the previously advanced EoE diagnostic panel (EDP), in a recent paper published in Gut (BMJ Journals), Gueguen et al. introduced a Histologically Active EoE Diagnostic Panel (HAEDP) effectively distinguishing patients with the active form of the disease from remission regardless of the fibrosis status and biopsy site. Here, we summarize recent findings and achievements in the development of the differential diagnosis of EoE based on the identification of unique deregulation in gene expression.","PeriodicalId":9694,"journal":{"name":"Central European Journal of Immunology","volume":"49 4","pages":"438-441"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interleukin 17A promotes glycolysis to activate human hepatic stellate cells by mediating the TRAF2/TRAF5/HuR/PFKFB3 axis.

IF 1.5 4区医学

Central European Journal of Immunology Pub Date : 2024-01-01 Epub Date: 2024-11-08 DOI: 10.5114/ceji.2024.145013

Tao Jiang, Shuangjie Li, Lian Tang, Yanfang Tan, Wenxian Ouyang

{"title":"Interleukin 17A promotes glycolysis to activate human hepatic stellate cells by mediating the TRAF2/TRAF5/HuR/PFKFB3 axis.","authors":"Tao Jiang, Shuangjie Li, Lian Tang, Yanfang Tan, Wenxian Ouyang","doi":"10.5114/ceji.2024.145013","DOIUrl":"10.5114/ceji.2024.145013","url":null,"abstract":"Introduction: Biliary atresia (BA) is an obliterating fibrous inflammatory bile duct disease in infants. Interleukin 17A (IL-17A) is abnormally expressed in patients with BA; however, the mechanism of its expression is unclear.Material and methods: Liver tissues from patients with BA and those with anicteric choledochal cysts (non-BA) were collected. The expression of genes and proteins was determined using RT-qPCR and western blot. Cell biological activities, including viability and proliferation, were evaluated by Cell Counting Kit-8 (CCK-8) and 5-ethynyl-2 '-deoxyuridine (EdU) assay. Glucose uptake and lactate and ATP levels were examined using commercial kits. The extracellular acidification rate (ECAR) level was evaluated by the XF96 Extracellular Flux analyzer. The interactions among TRAF2, TRAF5, and human antigen R (HuR) were validated using co-immunoprecipitation (Co-IP), RNA immunoprecipitation (RIP), and RNA pull-down.Results: In BA patients, IL-17A, TRAF2, TRAF5, and PFKFB3 were highly expressed, and IL-17A expression was positively correlated with PFKFB3, TRAF2, and TRAF5 expression, respectively. IL-17A elevated PFKFB3 expression and promoted glycolysis and the proliferation and fibrosis of hepatic stellate cells (HSCs), which were abolished by 2-deoxy-D-glucose (2-DG) and PFKFB3/TRAF2/TRAF5 silencing. Mechanistically, IL-17A promoted the interactions among HuR, TRAF2 and TRAF5 to form the TRAF2/TRAF5/HuR complex, thereby enhancing PFKFB3 expression.Conclusions: IL-17A facilitates glycolysis and HSC fibrosis by promoting TRAF2/TRAF5/HuR complex formation to regulate PFKFB3 expression.","PeriodicalId":9694,"journal":{"name":"Central European Journal of Immunology","volume":"49 4","pages":"404-424"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811719/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors. 接受局部治疗、靶向药物和 PD-1/PD-L1 抑制剂治疗的晚期肝细胞癌患者的病情进展模式。

IF 1.5 4区医学

Central European Journal of Immunology Pub Date : 2024-01-01 Epub Date: 2024-08-26 DOI: 10.5114/ceji.2024.142418

Yanan Zhao, Di Wu, Quanjun Yao, Hang Yuan, Hongtao Hu, Hailiang Li

{"title":"Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors.","authors":"Yanan Zhao, Di Wu, Quanjun Yao, Hang Yuan, Hongtao Hu, Hailiang Li","doi":"10.5114/ceji.2024.142418","DOIUrl":"https://doi.org/10.5114/ceji.2024.142418","url":null,"abstract":"Introduction: To explore the progression patterns of advanced hepatocellular carcinoma (HCC) in patients treated with a combination of local therapies, targeted drugs, and PD-1/PD-L1 inhibitors.Material and methods: A retrospective study involving 86 patients with Barcelona Clinic Liver Cancer stage C HCC was conducted between August 2018 and April 2022. All patients received local therapy, targeted drugs, and PD-1/PD-L1 inhibitors. Disease progression was evaluated using computed tomography or magnetic resonance imaging after combination therapy. Peripheral blood immune cells were analyzed using flow cytometry.Results: For intrahepatic progression, the median time to first progression was 5.3 months in 60 patients (95% confidence interval (CI): 2.3-7.1 months), and the median time to second progression was 9.3 months in 40 patients (95% CI: 4.8-11.8 months, p < 0.0001). For extrahepatic progression, the median time to first progression was 5.8 months in 61 patients (95% CI: 1.6-8.4 months), and the median time to second progression was 8.7 months in 39 patients (95% CI: 4.5-10.9 months, p < 0.0001). The common sites of extrahepatic progression are the lymph nodes and lungs. The percentages of PD-1+ cells gradually decreased after combination treatment but then gradually increased at follow-up in extrahepatic progression. The percentages of CD3+ T cells, CD3+CD4+ T cells, CD3+CD8+ T cells and CD16+CD56+ cells exhibited different trends in intrahepatic and extrahepatic progression.Conclusions: After combination treatment, patients with advanced HCC exhibit different characteristics of disease progression and composition of peripheral blood immune cells. Lymph nodes and lungs were the most susceptible sites for disease progression.","PeriodicalId":9694,"journal":{"name":"Central European Journal of Immunology","volume":"49 2","pages":"147-154"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0